Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology compan
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology compan